Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Shenyang Pharma Univ. hCA II compound 8d
- Development stage
- Unknown
- Lead developer
- Shenyang Pharmaceutical University
01
Overview
Shenyang Pharma Univ. hCA II compound 8d: sourced facts only. name: "Among them, compound 8d was the most effective inhibitor with IC50 of 60 nM against hCA II." [PMID:34728369]; target: "Among them, compound 8d was the most effective inhibitor with IC50 of 60 nM against hCA II." [PMID:34728369]; developer: "Key Laboratory of Structure-Based Drugs Design and Discovery (Ministry of Education), School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, Shenyang 110016, China." [PMID:34728369]
02
Targets
CA2 (Carbonic Anhydrase 2)
Beyond the preview
Go deeper on Shenyang Pharma Univ. hCA II compound 8d.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shenyang Pharma Univ. hCA II compound 8d.